IMMUNOVANT INC (IMVT:NASDAQ)
$24.5 -1.15 (-4.4834%)
Analysed IMMUNOVANT INC (IMVT:NASDAQ) News Sources
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints
06-04-2026
yahoo.com
Should Brepocitinib’s New Trials and Batoclimab’s Setback Require Action From Roivant Sciences (ROIV) Investors?
03-04-2026
yahoo.com
Sector Update: Health Care Stocks Softer Late Afternoon
02-04-2026
yahoo.com
Sector Update: Health Care Stocks Softer Thursday Afternoon
02-04-2026
yahoo.com
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP
02-04-2026
marketbeat.com
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM
02-04-2026
biopharmadive.com
Immunovant shares plunge after phase 3 trials fails to meet primary endpoint
02-04-2026
yahoo.com
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
02-04-2026
yahoo.com
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
02-04-2026
yahoo.com
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
15-03-2026
fool.com
What is the current price of IMMUNOVANT INC (IMVT:NASDAQ)?
The current price of IMMUNOVANT INC (IMVT:NASDAQ) is $24.5.
IMMUNOVANT INC (IMVT:NASDAQ) absolute price change since previous trading day?
The absolute price change of IMMUNOVANT INC (IMVT:NASDAQ) since the previous trading day is $-1.15.
IMMUNOVANT INC (IMVT:NASDAQ) percentage price change since previous trading day?
The percentage price change of IMMUNOVANT INC (IMVT:NASDAQ) since the previous trading day is -4.4834%.
What is the most recent average sentiment score for IMMUNOVANT INC (IMVT:NASDAQ)?
The most recent average sentiment score for IMMUNOVANT INC (IMVT:NASDAQ) is 46 out of 100.
What is the most recent average sentiment for IMMUNOVANT INC (IMVT:NASDAQ)?
The most recent sentiment for IMMUNOVANT INC (IMVT:NASDAQ) is .
SEC-8K** Filing Available For IMMUNOVANT INC (IMVT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.